Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 2Neoplasms 2Mesothelioma 2Triple Negative Breast Neoplasms 1Thymoma 1Ovarian Neoplasms 1Medical Oncology 1Lung Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Sunitinib 3Thymectomy 2Taxes 2Prednisone 2Pemetrexed 2Paclitaxel 2Octreotide 2Imatinib Mesylate 2Erlotinib Hydrochloride 2Cisplatin 2Carboplatin 2vorolanib 1regorafenib 1pembrolizumab 1olaparib 1lenvatinib 1entinostat 1bosutinib 1belinostat 1atezolizumab 1anetumab ravtansine 1amrubicin 1Ramucirumab 1Radiotherapy 1Radiosurgery 1Radiofrequency Ablation 1Psychiatric Rehabilitation 1Prednisolone 1Patient Comfort 1Palliative Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thymoma × anetumab ravtansine × Clear all
NCT03102320 2022-06-30

ARCS-Multi

Bayer

Phase 1 Completed
173 enrolled
BreastGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Thymoma, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡